Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

25 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Horizant Articles

XenoPort reports Horizant "stockout" due to GSK manufacturing delays

12 April 2013

GlaxoSmithKline gives up on XenoPort Horizant collaboration

9 November 2012

FDA clears GlaxoSmithKline's Horizant for PHN

8 June 2012

Backing for Japanese approval of Regnite, Ranmark and Cancidas

5 December 2011

FDA filings for Ironwood and Forest for linaclotide, and GSK and XenoPort for Horizant ER

10 August 2011

AstraZeneca’s vandetanib and GSK/XenoPort’s Horizant get US approval

7 April 2011

GlaxoSmithKline and XenoPort respond to FDA on Horizant for RLS; Pozen gets positive advisory recommendation on GI drug

8 November 2010

EPO Rules European Patent for XenoPort’s XP13512 is valid; Almirall grants Eisai marketing rights to cinitapride in China

16 April 2010

Showing 1-8 of 8 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS